Comparing a novel solubilized benzoyl peroxide gel with benzoyl peroxide/clindamycin: Final data from a multicenter, investigator-blind, randomized study

Journal of Drugs in Dermatology

Volumn 8, Issue 9, 2009, Pages 812-818

  Kircik, Leon ^a   Green, Lawrence ^b   Thiboutot, Diane ^c   Tanghetti, Emil ^d   Wilson, David ^e   Dhawan, Sunil ^f   Parr, Lisa ^g  

^a Physicians Skin Care PLLC   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

^d Center for Dermatology and Laser Surgery   (United States)

^e Education and Research Foundation   (United States)

^f Center for Dermatology Cosmetic and Laser Surgery   (United States)

^g OMP Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE; BENZOYL PEROXIDE PLUS CLINDAMYCIN; ANTIINFECTIVE AGENT; CLINDAMYCIN; DERMATOLOGICAL AGENT;

ACNE VULGARIS; ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ERYTHEMA; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SKIN ABRASION; SKIN BURNING SENSATION; SKIN PRURITUS; TREATMENT DURATION; BIOAVAILABILITY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; SOLUBILITY; TIME; TREATMENT OUTCOME;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; BIOLOGICAL AVAILABILITY; CHILD; CLINDAMYCIN; DERMATOLOGIC AGENTS; DRUG COMBINATIONS; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; SINGLE-BLIND METHOD; SOLUBILITY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349327580     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Belknap BS. Treatment of acne with 5% benzoyl peroxide gel or 0.05% retinoic acid cream. Cutis. 1979;23(6):856-859. (Pubitemid 9202646)
2. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05%, benzoyl peroxide gel 5% and placebo in patients with acne. Clin Exp Dermatol. 1992;17(3):165-168.
3. Leyden J. New developments in topical antimicrobial therapy for acne. J Drugs Dermatol. 2008;7(2 Suppl):s8-s11.
4. Chellquist EM, Gorman WG. Benzoyl peroxide solubility and stability in hydric solvents. Pharm Res. 1992;9(10):1341-1346.
5. Nielloud F, Mestres JP, Marti-Mestres G. Consideration on the formulation of benzoyl peroxide at ambient temperature: Choice of non-polar solvent and preparation of submicron emulsion gels. Drug Dev Ind Pharm. 2002;28(7):863-870. (Pubitemid 34977804)
6. Erianne J, Prince DL, Ramirez J, et al. The pharmacologic science of a novel benzoyl peroxide formulation and the implications for clinical effects. Poster presented at the Academy '07 meeting of the American Academy of Dermatology, August 1-5, 2007, New York, NY.
7. Tanghetti E, Kircik L, Wilson D, Dhawan S. Solubilized benzoyl peroxide versus benzoyl peroxide/clindamycin in the treatment of moderate acne. A multicenter, investigator-blind, randomized study. J Drugs Dermatol. 2008;7(6):534-538.
8. Introducing SoluCLENZ Rx GelTM. Obagi Medical Products, Inc. web site. Available at: http://www.obagi.com/article/forpatients/ obagisoluclenzrx/ soluclenz.html. Accessed February 26, 2009.
9. CLENZIderm M.D.TM Product Overview. Obagi Medical Products, Inc. web site. Available at: http://www.obagi.com/article/forpatients/ obagiclenzidermmd/products/products.html. Accessed February 26, 2009.
10. Bowe WP, Shalita AR. Effective over-the-counter acne treatments. Semin Cutan Med Surg. 2008;27(3):170-176.
11. Thiboutot D, Eichenfield L, Shalita A, et al. A 3-step acne system containing solubilized benzoyl peroxide vs. benzoyl peroxide/clindamycin. Cutis. 2009 (in press).
12. Shalita A, Weiss JS, Chalker DK, et al. A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: A multicenter trial. J Am Acad Dermatol. 1996;34(3):482-485. (Pubitemid 26083828)
13. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1% gel versus tretinoin 0.025% gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol. 1998;139 Suppl 52:48-56.
14. Webster GF, Berson D, Stein LF, et al. Efficacy and tolerability of once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.025% gel in the treatment of facial acne vulgaris: a randomized trial. Cutis. 2001;67(6 Suppl):4-9.
15. Webster GF. Topical tretinoin in acne therapy. J Am Acad Dermatol. 1998;39(2 Pt 3):S38-S44. (Pubitemid 28367285)
16. Leyden JJ, Tanghetti EA, Miller B, et al. Once-daily tazarotene 0.1% gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: A double-blind randomized trial. Cutis. 2002;69(2 Suppl):12-19.
17. Webster GF, Guenther L, Poulin YP, et al. A multicenter, doubleblind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris. Cutis. 2002;69(2 Suppl):4-11.
18. Thiboutot D, Pariser DM, Egan N, et al. Adapalene gel 0.3% for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol. 2006;54(2):242-250. (Pubitemid 43144393)
19. Differin® (adapalene) gel, 0.3% package insert. Galderma Laboratories, L.P. web site. Available at: http://www.differin.com/ AboutDifferin/ ProductInsert-Gel03.aspx. Accessed February 5, 2009.
20. Shalita A, Miller B, Menter A, et al. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol. 2005;4(2):153-158.
21. Differin® (adapalene) cream, 0.1% package insert. Galderma Laboratories, L.P. web site. Available at: http://www.differin.com/About- Differin/ProductInsert-Cream.aspx. Accessed January 26, 2009.
22. Shalita AR, Chalker DK, Griffi th RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: A multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63(6):349-354.
23. Tazorac® gel prescribing information. Allergan, Inc. web site. Available at: http://www.allergan.com/assets/pdf/tazorac-gel-pi.pdf. Accessed January 26, 2009.
24. Tazorac® cream prescribing information. Allergan, Inc. web site. Available at: http://www.allergan.com/assets/pdf/tazorac-cream-pi.pdf. Accessed January 26, 2009